Education
About Us
Working with TipRanks
Follow Us
BioNxt Solutions (TSE:BNXT)
:BNXT
BNXT Stock Chart & Stats
C$0.64
-C$0.02(-3.85%)
At close: 4:00 PM EST
C$0.64
-C$0.02(-3.85%)
Day’s Range― - ―
52-Week RangeC$0.38 - C$1.10
Previous CloseN/A
Volume110.36K
Average Volume (3M)80.86K
Market Cap
C$75.52M
Enterprise ValueC$89.48M
Total Cash (Recent Filing)C$468.76K
Total Debt (Recent Filing)C$8.33M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding121,810,260
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)-5.39
Price to Sales (P/S)1568.84
P/FCF Ratio-13.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash Burn TrendThe company reports that losses and cash burn have moderated versus the weakest 2021–2022 period. A sustained reduction in cash outflow pace can extend runway, lower near-term refinancing pressure, and provide management time to execute restructuring or commercialization plans.
Lean Cost BaseA very small headcount suggests a lean operating model, which can conserve cash and allow flexibility in scaling R&D or commercialization spending. For a cash‑burning biotech/specialty drug firm, low fixed cost structure materially lengthens runway per financing round.
Industry Structural DemandOperating in specialty and generic pharmaceuticals exposes the firm to durable demand for essential medicines and recurring revenue opportunities. Structural industry needs, regulatory barriers to entry, and long product lifecycles can support sustained revenue once products reach stable commercialization.
Bears Say
Negative Shareholders' EquityNegative equity denotes solvency pressure and limited balance sheet flexibility. It raises refinancing and dilution risk, constrains access to conventional credit, and signals that accumulated losses have materially eroded investor capital—impairing long‑term financial resilience.
Persistent Operating Cash BurnContinued negative operating and free cash flow indicates the business cannot self‑fund operations and must rely on external financing. Over months this amplifies dilution or refinancing risk, limits strategic optionality, and pressures management to secure funding rather than invest in growth.
Sharply Declining RevenueMaterial year‑over‑year revenue decline undermines the path to sustainable profitability and scaling. Falling top line reduces leverage to cover fixed costs, lengthens time to breakeven, and impairs investor confidence in commercial viability absent clear product or market inflection catalysts.
BioNxt Solutions News
BNXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was C$0.38 and its highest was C$1.10 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is C$75.52M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Apr 29, 2026 which is in 66 days.
How were BioNxt Solutions’s earnings last quarter?
BioNxt Solutions released its earnings results on Nov 26, 2025. The company reported -C$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.014.
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 121,810,260 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
BioNxt Solutions reported an EPS of -C$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in TSE:BNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---